April 19, 2010 8:03 AM EDT
Needham & Company reiterates a ‘Strong Buy’ rating on NuVasive Inc. (Nasdaq
: NUVA), price target $60.
Needham analyst says, “We expect significant upside to NUVA’s share price if NUVA continues to meet or beat numbers and demonstrates EPS leverage in 2010.”
To see all the upgrades/downgrades on shares of NUVA, visit our Analyst Ratings page.
NuVasive, Inc. (NuVasive) is a medical device company
. It focuses on the designing, developing and marketing of products for the surgical treatment of spine disorders.
